HC Wainwright & Co. Reiterates Buy on Actuate Therapeutics, Maintains $15 Price Target
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Actuate Therapeutics (NASDAQ:ACTU) with a Buy and maintains $15 price target.
Stocks · News reference
Actuate Therapeutics shares are trading higher after the company announced that elraglusib will be evaluated in the BEACON2 clinical trial to identify and advance treatment approaches for children with relapsed and refractory neuroblastoma.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
This SK Hynix Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday
Top Wall Street analysts changed their outlook on various stocks. Check out the analyst ratings page for upgrades, downgrades, and initiations.
Rodman & Renshaw Initiates Coverage On Actuate Therapeutics with Buy Rating, Announces Price Target of $6
8-K filing — ACTUATE THERAPEUTICS, INC. (ACTU)
Filed: 2026-07-17 AccNo: 0001683168-26-005616 Size: 205 KB Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing